Key Highlights
- Robert Lisicki assumes the role of CEO and Director at Zura Bio, succeeding founding CEO, Dr. Someit Sidhu.
- Zura Bio gears up for a critical phase of trial execution for tibulizumab in systemic sclerosis, with significant readouts expected in the next 24 months.
- Lisicki, with 30 years in the biopharmaceutical industry, brings a wealth of experience in strategy, commercial operations, and drug development.
Source: Business Wire
Notable Quotes
- “With a successful track record in strategy, commercial operations, and drug development, Robert is well suited to establish Zura Bio as a leading immunology company.” – Amit Munshi, Chairman at Zura Bio Board of Directors
- “I’m thrilled to take on this expanded role, and for the opportunity to lead such a talented and experienced team.” – Robert Lisicki, CEO and Director at Zura Bio
- “I would like to thank Dr. Someit Sidhu for his thoughtful partnership and look forward to working with him in his role as a Board Director.” – Robert Lisicki, CEO and Director at Zura Bio
SoHC's Take
Zura Bio’s strategic leadership transition underscores a pivotal moment in the company’s journey towards cementing its position as an immunology frontrunner. The appointment of Robert Lisicki, a seasoned leader with a notable track record in the biopharmaceutical sector, signals Zura Bio’s renewed commitment to advancing its pipeline of innovative autoimmune and inflammatory disease treatments. With Lisicki at the helm, Zura Bio is poised to leverage its promising drug candidates, notably tibulizumab, to address critical unmet needs in autoimmune therapy. This leadership change, coupled with a focus on critical trial milestones and strategic development, marks an exciting phase for Zura Bio as it aims to bring transformative therapies to patients worldwide.
